On January 6, 2021 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 3:40 PM ET (Press release, Precigen, JAN 6, 2021, View Source [SID1234573565]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sabzevari will also participate in a panel discussion hosted by Scott Gottlieb, MD, at the H.C. Wainwright BioConnect 2021 Conference on January 13, 2021 at 12:00 PM ET. The panel will explore precision medicine and the importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization.

Participants may access the live webcasts of the virtual events through Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.

On January 6, 2021 Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, reported that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications (Press release, Kite Pharma, JAN 6, 2021, View Source [SID1234573564]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this collaboration, OBT will validate five novel oncology drug targets, previously identified using OBT’s OGAP discovery platform, and generate antibodies against these targets. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies.

"As the leader in cell therapy, we are committed to continuing to bring its transformative potential to more patients with different kinds of cancers," said Mert Aktar, Vice President of Corporate Development and Strategy at Kite. "We’re excited to partner with Oxford BioTherapeutics to help accelerate this research by identifying new targets in solid tumors and hematologic malignancies where novel approaches may help improve outcomes."

Dr. Christian Rohlff, OBT’s Chief Executive Officer said, "Selecting the right target is fundamental for the successful development of first-in-class cell therapies. OBT’s state-of-the-art platforms have refined this approach to address difficult-to-treat cancers. This has resulted in several candidates entering clinical development either by OBT or its development partners. We are delighted that Kite, the global leader in cell therapy, has recognized the potential of OBT’s OGAP discovery platform and antibody capabilities through this partnership. On behalf of patients in urgent need of novel therapies, we look forward to working with Kite to advance cell therapies for the treatment of hematologic malignancies and solid tumors."

Under the terms of the agreement, OBT will receive an upfront payment and will be eligible to receive additional payments based on achievement of certain discovery, clinical and regulatory milestones, as well as royalties on future potential sales.

On January 6, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 – 14, 2021 (Press release, Akebia, JAN 6, 2021, View Source/news-releases/news-release-details/akebia-therapeutics-present-hc-wainwright-bioconnect-2021" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-present-hc-wainwright-bioconnect-2021" rel="nofollow">View Source [SID1234573563]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The recorded presentation will be available on the Investors section of the Company’s website at View Source beginning Monday, January 11.

On January 6, 2021 UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, reported that Liz Barrett, President and Chief Executive Officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 p.m. Eastern Time (Press release, UroGen Pharma, JAN 6, 2021, View Source [SID1234573562]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation and Q&A session will be webcast live and can be accessed by visiting the Investors & Media section of UroGen’s website at www.urogen.com. A replay will be available on the Company’s website for approximately 30 days.

On January 6, 2021 Pacira BioSciences, Inc. (NASDAQ: PCRX) reported that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 7:30 AM ET on Wednesday, January 13, 2021 (Press release, Pacira Pharmaceuticals, JAN 6, 2021, View Source [SID1234573561]). Live audio of the virtual event can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!